safetyriskБезопасность и риск фармакотерапииSafety and Risk of Pharmacotherapy2312-78212619-1164Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)safetyrisk-298Research ArticleОБЗОРЫ И ОРИГИНАЛЬНЫЕ СТАТЬИREVIEWS AND ORIGINAL ARTICLESК вопросу ацетаминофена о безопасностиOn the safety of acetaminophenАляутдинР. Н.AlyautdinR. N.РомановБ. К.LepakhinV. K.ЛепахинВ. К.RomanovB. K.ПереверзевА. П.PereverzevA. P.Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской Федерации, МоскваРоссияScientific Centre for Expert Evaluation of Medicinal Products Russian FederationRussian Federation2014310520220259Copyright © Аляутдин Р.Н., Романов Б.К., Лепахин В.К., Переверзев А.П., 20222022Аляутдин Р.Н., Романов Б.К., Лепахин В.К., Переверзев А.П.Alyautdin R.N., Lepakhin V.K., Romanov B.K., Pereverzev A.P.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.risksafety.ru/jour/article/view/298

Ацетаминофен является одним из наиболее часто используемых анальгетиков/антипиретиков. Вместе с тем, учитывая существующий риск развития гепатотоксического действия регуляторные органы ряда стран внесли дополнительные корректировки в рекомендации по использованию этого препарата. В статье обсуждаются возможные причины обращения к ацетаминофену.

Acetaminophen is one of the most commonly used analgesics /anti pyretics. However, taking into account the existing risk of hepatotoxicity,regulatory bodies of a number of the countries made additional adjustments tothe recommendations on the use of this drug. In the article the possible reasonsfor recourse to acetaminophen are discussed

ацетаминофенлекарственное взаимодействиегепатоксичностьacetaminophendrug interactionhepatotoxicityReferenceshttp://www.fda.gov/Drugs/DrugSafety/ucm381644.htm.www.tga.gov.auhttp://www.fda.gov/Drugs/DrugSafety/ucm381644.htm.www.tga.gov.auToussaint K., Yang X.C., Zielinski M.A. What do we (not) know about how paracetamolToussaint K., Yang X.C., Zielinski M.A. What do we (not) know about how paracetamol(acetaminophen) works? // J. Clin. Pharm. Ther. 2010. V. 35. P. 617–638(acetaminophen) works? // J. Clin. Pharm. Ther. 2010. V. 35. P. 617–638Hinz В., Cheremin a О., Brune К. Acetaminophen (paracetamol) is a selective cyclooxygenHinz В., Cheremin a О., Brune К. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB.// 2008. V. 22. P. 383-390ase-2 inhibitor in man. FASEB.// 2008. V. 22. P. 383-390Oscier C.D., Milner O. Peri-operative use of paracetamol.// An aesthesia. 2009.V. 64. P.Oscier C.D., Milner O. Peri-operative use of paracetamol.// An aesthesia. 2009.V. 64. P.–72–72Pierre S.C., Schmidt R., BrenneisC., et al. Inhibition of Cyclooxygen ases by Di pyrone.//Pierre S.C., Schmidt R., BrenneisC., et al. Inhibition of Cyclooxygen ases by Di pyrone.//Brit. J. Pharmacol. 2007. V.151. P. 494–503Brit. J. Pharmacol. 2007. V.151. P. 494–503Hanel AM, Lands WE. Modification of anti-inflammatory drug effectiveness by ambientHanel AM, Lands WE. Modification of anti-inflammatory drug effectiveness by ambientli pid peroxides. Biochem. Pharmacol.// 1982. V.33. P. 3307–3311.li pid peroxides. Biochem. Pharmacol.// 1982. V.33. P. 3307–3311.Tjolsen A, Lund A, Hole K. Antinociceptive effect of paracetamol in rats is partly dependentTjolsen A, Lund A, Hole K. Antinociceptive effect of paracetamol in rats is partly dependenton spin al serotonergic systems.// Eur. J. Pharmacol. 1991.V.193. P.193–201.on spin al serotonergic systems.// Eur. J. Pharmacol. 1991.V.193. P.193–201.Zygmunt PM, Chuang H, Movahed P, et al. The an andamide transport inhibitor AM404Zygmunt PM, Chuang H, Movahed P, et al. The an andamide transport inhibitor AM404activates vanilloid receptors.// Eur. J. Pharmacol. 2000.V.396. P.39–42.activates vanilloid receptors.// Eur. J. Pharmacol. 2000.V.396. P.39–42.Bjorkman R., Hallman K.M., Hedner T., Henning M. Acetaminophen blocks spin al hyperalgesiaBjorkman R., Hallman K.M., Hedner T., Henning M. Acetaminophen blocks spin al hyperalgesiainduced by NMDA and substance P.// Pain. 1994. V.57. P.259–264.induced by NMDA and substance P.// Pain. 1994. V.57. P.259–264.Barden J., Edwards J., Moore A., McQuay H. Single dose oral paracetamol (acetaminophen)Barden J., Edwards J., Moore A., McQuay H. Single dose oral paracetamol (acetaminophen)for postoperative pain.// Cochrane Database of Systematic Rev. 2004. V. 1: CD004602.for postoperative pain.// Cochrane Database of Systematic Rev. 2004. V. 1: CD004602.Weil K, Hooper L, Afzal Z, et al. Paracetamol for pain relief after surgical removal ofWeil K, Hooper L, Afzal Z, et al. Paracetamol for pain relief after surgical removal oflower wisdom teeth.// Cochrane Database of Systematic Rev. 2007. V. 3. CD004487.lower wisdom teeth.// Cochrane Database of Systematic Rev. 2007. V. 3. CD004487.Corcoran G.B., Racz W.J., Smith C.V. and Mitchel, J.R. Effects of N-acetylcysteine onCorcoran G.B., Racz W.J., Smith C.V. and Mitchel, J.R. Effects of N-acetylcysteine onacetaminophen covalent binding and hepatic necrosis in mice.// J. Pharmacol. Exp. Ther.acetaminophen covalent binding and hepatic necrosis in mice.// J. Pharmacol. Exp. Ther.V. 232. P. 864-872V. 232. P. 864-872Forrest J., Adriaenssens P., Finlayson N.D., Prescott L.F. Paracetamol metabolism inForrest J., Adriaenssens P., Finlayson N.D., Prescott L.F. Paracetamol metabolism inchronic liver disease.// Eur. J. Clin. Pharmac. 1979.V. 15. P. 427–31.chronic liver disease.// Eur. J. Clin. Pharmac. 1979.V. 15. P. 427–31.Bertolini A., FerrariA., Ottani A.et al. Paracetamol: New Vistas of an Old Drug. CNSBertolini A., FerrariA., Ottani A.et al. Paracetamol: New Vistas of an Old Drug. CNSDrug Reviews//. 2006. No. 3–4, 250-275Drug Reviews//. 2006. No. 3–4, 250-275Smidt L.E., Dalhoff A. The effect of regular medication on the outcome of paracetamolSmidt L.E., Dalhoff A. The effect of regular medication on the outcome of paracetamolpoisoning.// Aliment. Pharmacol. Ther. 2002.V. 1.P.: 1539–1545.poisoning.// Aliment. Pharmacol. Ther. 2002.V. 1.P.: 1539–1545.Sonne J., Poulsen H.E., Andreasen P.B. Single dose oxazepam has no effect on acetaminophenSonne J., Poulsen H.E., Andreasen P.B. Single dose oxazepam has no effect on acetaminophenclearance or metabolism.// Eur. J.Clin Pharmacol. 1986. V. 30.P. 127–129.clearance or metabolism.// Eur. J.Clin Pharmacol. 1986. V. 30.P. 127–129.Skoulis N.P., James R.C., Harbison R.D., Roberts S.M. Depression of hepatic glutathioneSkoulis N.P., James R.C., Harbison R.D., Roberts S.M. Depression of hepatic glutathioneby opioid an algesic drugs in mice.// Toxicol. Appl. Pharmacol. 1989. V. 99.P. 139–147.by opioid an algesic drugs in mice.// Toxicol. Appl. Pharmacol. 1989. V. 99.P. 139–147.Rumack B.H. Acetaminophen misconceptions//. Hepatology. 2004. V. 40.P. 10–15.Rumack B.H. Acetaminophen misconceptions//. Hepatology. 2004. V. 40.P. 10–15.Draganov .P, Durrence H., Cox C., Reuben A. Alcoholacetaminophen syndrome. EvenDraganov .P, Durrence H., Cox C., Reuben A. Alcoholacetaminophen syndrome. Evenmoderate social drinkers are at risk.// Postgrad. Med. 2000. V.107. P. 189–195.moderate social drinkers are at risk.// Postgrad. Med. 2000. V.107. P. 189–195.Kuffner EK, Dart RC, Bogdan GM, Hill RE, Casper E, Darton L. Effect of maximal dailyKuffner EK, Dart RC, Bogdan GM, Hill RE, Casper E, Darton L. Effect of maximal dailydoses of acetaminophen on the liver of alcoholic patients: a randomized double-blinddoses of acetaminophen on the liver of alcoholic patients: a randomized double-blindplacebo-controlled trial.// Arch. Intern. Med. 2001. V. 161. P. 2247–2252.placebo-controlled trial.// Arch. Intern. Med. 2001. V. 161. P. 2247–2252.Heard K., Green J..L, Bailey J.E.et al. A randomized trial to determine the change in alanineHeard K., Green J..L, Bailey J.E.et al. A randomized trial to determine the change in alanineaminotransferase during 10 days of paracetamol (acetaminophen) administration inaminotransferase during 10 days of paracetamol (acetaminophen) administration insubjects who consume moderate amounts of alcohol.// Alimentary Pharmac. Ther. 2007.subjects who consume moderate amounts of alcohol.// Alimentary Pharmac. Ther. 2007.V. 26.P. 283–290.V. 26.P. 283–290.Prescott.L.E. Paracetamol, alcohol and the liver.// Br. J. Clin. Pharmacol. 2006. V.49. P. 291-301Prescott.L.E. Paracetamol, alcohol and the liver.// Br. J. Clin. Pharmacol. 2006. V.49. P. 291-301Lauterburg B.H., Velez M.E. Glutathione deficiency in alcoholics: Risk factor for paracetamolLauterburg B.H., Velez M.E. Glutathione deficiency in alcoholics: Risk factor for paracetamolhepatotoxicity.// Gut. 1988. V. 29. P.1153–1157.hepatotoxicity.// Gut. 1988. V. 29. P.1153–1157.Lauterburg B.H., Velez M.E. Glutathione deficiency in alcoholics: Risk factor for paracetamolLauterburg B.H., Velez M.E. Glutathione deficiency in alcoholics: Risk factor for paracetamolhepatotoxicity.// Gut. 1988. V. 29. P.1153–1157hepatotoxicity.// Gut. 1988. V. 29. P.1153–1157

The authors declare that there are no conflicts of interest present.